Humana Inc. (NYSE:HUM) Receives $297.68 Consensus Target Price from Analysts

Humana Inc. (NYSE:HUM) has earned an average recommendation of “Hold” from the twenty-four research firms that are covering the firm, MarketBeat reports. Nineteen analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $297.68.

Several research analysts have weighed in on the company. Truist Financial upped their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. TD Cowen upped their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. KeyCorp began coverage on Humana in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Barclays upped their price target on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. Finally, Stephens reiterated an “equal weight” rating and set a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th.

Humana Stock Performance

Shares of HUM stock opened at $290.52 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The stock’s 50-day moving average is $275.13 and its two-hundred day moving average is $299.72. The firm has a market cap of $34.98 billion, a P/E ratio of 25.73, a PEG ratio of 2.21 and a beta of 0.56.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.29% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. FNY Investment Advisers LLC boosted its stake in shares of Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after purchasing an additional 26,856 shares during the last quarter. Retirement Systems of Alabama raised its position in shares of Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after acquiring an additional 192,801 shares during the period. PDT Partners LLC raised its position in shares of Humana by 190.0% in the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after acquiring an additional 2,660 shares during the period. Secure Asset Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at approximately $244,000. Finally, Ontario Teachers Pension Plan Board raised its position in shares of Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after acquiring an additional 71,910 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.